GFAP and Alzheimer disease: At 10 weeks post EV‐treatment, GFAP expression levels were significantly decreased in the mPFC region of both hNSC‐ and iMGL‐EV‐treated AD mice compared to the vehicle‐treated AD group (Figure 4B; p < 0.01), but not for the PRh region (Figure S4D).